ArticleNature communications2017
Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 108 citations in OpenAlex.
- In Situ Lipoprotein-seeking Dye for in Vivo Real-Time Imaging of Lipid Dysregulation Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Ecdysteroid-Containing Squalenoylated Self-Assembling Nanoparticles Exert Tumor-Selective Sensitization to Reactive Oxygen Species (ROS)-Induced Oxidative Damage While Protecting Normal Cells: Implications for Selective Radiotherapy.Journal of medicinal chemistry · 2025Article
- Lymphatic uptake and pharmacokinetics of lipid conjugated brush PEG polymers is altered by interactions with albumin and lipoproteins.Frontiers in physiology · 2025Article
- Novel Spectroscopic Studies of the Interaction of Three Different Types of Iron Oxide Nanoparticles with Albumin.Nanomaterials (Basel, Switzerland) · 2024Article
- Gemcitabine-Vitamin E Prodrug-Loaded Micelles for Pancreatic Cancer Therapy.Pharmaceutics · 2024Article
- Astrocyte-targeted siRNA delivery by adenosine-functionalized LNP in mouse TBI model.Molecular therapy. Nucleic acids · 2023Article
- Improving the Stability and Effectiveness of Immunotropic Squalene Nanoemulsion by Adding Turpentine Oil.Biomolecules · 2023Article
- Tumor-Activatable Nanoparticles Target Low-Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Supramolecular nanomedicines through rational design of self-assembling prodrugs.Trends in pharmacological sciences · 2022Review
- From Sharks to Yeasts: Squalene in the Development of Vaccine Adjuvants.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Combinatorial nanococktails via self-assembling lipid prodrugs for synergistically overcoming drug resistance and effective cancer therapy.Biomaterials research · 2022Article
- Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy.Asian journal of pharmaceutical sciences · 2022Review
- Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness.International journal of nanomedicine · 2022Article
- Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.Bioengineered · 2021Article
- Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles.Pharmaceutical research · 2021Review
- Targeting Systems to the Brain Obtained by Merging Prodrugs, Nanoparticles, and Nasal Administration.Pharmaceutics · 2021Review
- Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis.Journal of clinical medicine · 2021Review
- Nanoparticle-Based Approaches towards the Treatment of Atherosclerosis.Pharmaceutics · 2020Review
- Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Once introduced in the organism, the interaction of nanoparticles with various biomolecules strongly impacts their fate. Here we show that nanoparticles made of the squalene derivative of gemcitabine (SQGem) interact with lipoproteins (LPs), indirectly enabling the targeting of cancer cells with high LP receptors expression. In vitro and in vivo experiments reveal preeminent affinity of the squalene-gemcitabine bioconjugates towards LP particles with the highest cholesterol content and in silico simulations further display their incorporation into the hydrophobic core of LPs. To the best of our knowledge, the use of squalene to induce drug insertion into LPs for indirect cancer cell targeting is a novel concept in drug delivery. Interestingly, not only SQGem but also other squalene derivatives interact similarly with lipoproteins while such interaction is not observed with liposomes. The conjugation to squalene represents a versatile platform that would enable efficient drug delivery by simply exploiting endogenous lipoproteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.